Search clinical trials for: SHR- A1811

Total 1785 results

Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

HER2 Expression / Amplification in Patients With Biliary Tract Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Atridia Pty Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumors

China, Korea, Republic of, Taiwan, United States, Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Gastric Cancer | Colorectal Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

HER2-expressing Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Beijing GoBroad Hospital

Not yet recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Breast Cancer

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Fudan University

Active, not recruiting

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Breast Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

HER2 Low Advanced or Metastatic Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Recruiting

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Advanced Salivary Gland Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

China
Huihua Xiong

Not yet recruiting

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Breasr Cancer
Henan Cancer Hospital

Recruiting

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Metastatic Breast Cancer

China
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Sanjay Gandhi Postgraduate Institute of Medical...
Ram Manohar Lohia Institute of Medical Sciences, Lucknow

Terminated

Re-treatment of HCV Following DAA Failure

Chronic Hepatitis C

India
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

T2DM

China
Atridia Pty Ltd.

Completed

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

Australia
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Advanced Solid Tumors
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

IgA Nephropathy

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects

Prevention of Arterial and Venous Thrombosis

China

3

Subscribe